Skip to main
STOK

STOK Stock Forecast & Price Target

STOK Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 22%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Stoke Therapeutics is facing a key event with the completion of enrollment for their P3 Dravet syndrome study, and given the recent 36-month data for zorevunersen demonstrating non-seizure improvement, it seems likely ZOLGENSMA followed by SPINRAZA or other drugs. Their lead candidate for Dravet syndrome, zorevunersen, could generate potential peak annual sales exceeding $1 billion and we feel positively about its ASO as a treatment for Autosomal Dominant Optic Atrophy. Considering a WACC of 13%, our 12-month price target is $35 per share for this development stage company and we see potential for future revenue streams from other targets being pursued by Stoke's broad applicability in addressing hundreds of disease states.

Bears say

Stoke Therapeutics is facing high operating losses and large net losses, making it financially unstable. While its TANGO platform and lead asset zorevunersen offer potential in treating genetic disorders, there are significant risks associated with intellectual property rights and regulatory approvals. Additionally, the company relies on data from third-party CROs, which could negatively affect its drug development process. Furthermore, there are concerns about potential share dilution for shareholders and the high ownership of Skorpios Trust, which could result in stock price volatility. Overall, the company's uncertain financials and potential risks in its drug development process make us hold a negative view on Stoke Therapeutics' stock.

STOK has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stoke Therapeutics Inc (STOK) Forecast

Analysts have given STOK a Strong Buy based on their latest research and market trends.

According to 9 analysts, STOK has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stoke Therapeutics Inc (STOK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.